Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297309 · ClinicalTrials.gov registry record · Phase 3
A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT01297309 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 51 participants.
The verdict
NCT01297309, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.
Interventions
- DRUG NPSP558
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-04-06 |
| Est. Completion | 2018-06-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01297309
The ClinicalTrials.gov registry entry for NCT01297309 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NPSP558 is the first listed.
NCT01297309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01297309 about?
NCT01297309 is a clinical study titled "A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)". This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.
What is the current status of trial NCT01297309?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2011-04-06. Estimated completion is 2018-06-08.
What interventions are being tested in trial NCT01297309?
The interventions under investigation include: NPSP558 (DRUG).
Who is sponsoring clinical trial NCT01297309?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.